X0306 4 2023-02-14 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817160 Hansen Gwenn C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Scientific Officer Employee Stock Option (right to buy) 10.83 2023-02-14 4 A 0 88900 0.00 A 2033-02-13 Common Stock 88900 88900 D Restricted Stock Units 0.00 2023-02-14 4 A 0 24000 0.00 A Common Stock 24000 24000 D The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. Exhibit 24 - Power of Attorney /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen 2023-02-15